Impact of adjuvant radiotherapy on the survival of women with optimally resected stage III endometrial cancer in the era of modern radiotherapy: a retrospective study

Table 3 Univariate analysis of potential prognostic factors (n = 154)

	5-year RFS	HR (95% CI)	p-value^a	5-year OS	HR (95% CI)	p-value^a
Age			0.008			0.459
≤ 60 years	76	–		86	–
> 60 years	52	2.14 (1.20–3.79)		81	1.41 (0.57–3.51)
FIGO stage			0.451			0.615
IIIA or IIIB	69	–		85	–
IIIC	66	0.89 (0.65–1.21)		84	0.88 (0.55–1.43)
Histology			< 0.001			0.001
Endometrioid	75	–		87	–
Non-endometrioid	15	5.42 (2.88–10.18)		62	4.34 (1.63–11.60)
Tumor grade			< 0.001			0.043
1–2	78	–		88	–
3	44	1.74 (1.30–2.32)		76	1.49 (1.05–2.35)
Lymphovascular space invasion			0.950			0.232
Nil	69	–		87	–
Present	64	1.01 (0.71–1.37)		76	1.32 (0.83–2.11)
Peritoneal cytology			0.174			0.316
Negative	70	–		86	–
Positive	58	1.54 (0.82–2.89)		75	1.64 (0.62–4.33)
≥2 positive LN			0.545			0.316
Nil	69	–		87	–
Present	66	1.19 (0.67–2.12)		82	1.59 (0.64–3.95)
Adjuvant radiotherapy, alone or combined with chemotherapy			0.046			0.065
Yes	75	0.62 (0.35–0.99)		85	0.53 (0.21–1.23)
No	61	–		80	–
Adjuvant chemotherapy, alone or combined with radiotherapy			0.838			0.965
Yes	69	1.08 (0.52–2.25)		82	1.03 (0.34–3.07)
No	73	–		85	–
Combined chemoradiotherapy			0.084			0.522
Yes	81	0.48 (0.20–1.13)		87	0.67 (0.19–2.31)
No	64	–		84	–

FIGO The International Federation of Gynecology and Obstetrics, LN lymph node, RFS recurrence-free survival, OS overall survival, HR hazard ratio, CI confidence interval
^aSignificance tested using Kaplan–Meier life table analysis and the log-rank test

ISSN: 1748-717X